Halozyme Therapeutics, Inc. (HALO)
USD 57.78
(-3.33%)
USD 57.78
(-3.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 451.94 Million USD | 35.97% |
| 2022 | 315.5 Million USD | 12.6% |
| 2021 | 259.04 Million USD | 91.26% |
| 2020 | 152.96 Million USD | 313.36% |
| 2019 | -56.55 Million USD | 2.48% |
| 2018 | -69.33 Million USD | -185.59% |
| 2017 | 83.16 Million USD | 197.35% |
| 2016 | -79.47 Million USD | -203.11% |
| 2015 | -25.35 Million USD | 56.45% |
| 2014 | -61.03 Million USD | 21.63% |
| 2013 | -78.97 Million USD | -49.99% |
| 2012 | -52.47 Million USD | -170.23% |
| 2011 | -18.67 Million USD | 63.06% |
| 2010 | -52.74 Million USD | 5.78% |
| 2009 | -56.91 Million USD | -15.44% |
| 2008 | -49.38 Million USD | -79.11% |
| 2007 | -28.15 Million USD | -79.76% |
| 2006 | -14.5 Million USD | -12.45% |
| 2005 | -13.35 Million USD | -52.23% |
| 2004 | -8.96 Million USD | -11229.95% |
| 2003 | -79.09 Thousand USD | -452.66% |
| 2002 | -14.31 Thousand USD | 64.01% |
| 2001 | -39.76 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 137.59 Million USD | 18.88% |
| 2024 Q1 | 115.74 Million USD | -8.92% |
| 2024 Q3 | 163.19 Million USD | 38.11% |
| 2023 Q2 | 115.08 Million USD | 60.65% |
| 2023 Q3 | 108.62 Million USD | -5.62% |
| 2023 Q4 | 121.72 Million USD | 12.07% |
| 2023 FY | - USD | 35.97% |
| 2023 Q1 | 71.63 Million USD | -9.39% |
| 2022 Q3 | 112.49 Million USD | 141.37% |
| 2022 Q1 | 76.44 Million USD | 35.22% |
| 2022 Q2 | 46.6 Million USD | -39.04% |
| 2022 FY | - USD | 12.6% |
| 2022 Q4 | 79.06 Million USD | -29.72% |
| 2021 FY | - USD | 91.26% |
| 2021 Q4 | 56.53 Million USD | -25.94% |
| 2021 Q3 | 76.33 Million USD | -18.6% |
| 2021 Q2 | 93.78 Million USD | 82.2% |
| 2021 Q1 | 51.47 Million USD | -33.69% |
| 2020 Q2 | 30.37 Million USD | 1383.98% |
| 2020 Q1 | -2.36 Million USD | 92.62% |
| 2020 Q3 | 41.1 Million USD | 35.3% |
| 2020 FY | - USD | 313.36% |
| 2020 Q4 | 77.62 Million USD | 88.86% |
| 2019 Q2 | -12.94 Million USD | -427.17% |
| 2019 Q3 | -23.53 Million USD | -81.84% |
| 2019 Q4 | -32.06 Million USD | -36.23% |
| 2019 FY | - USD | 2.48% |
| 2019 Q1 | 3.95 Million USD | 5671.83% |
| 2018 Q1 | -23.14 Million USD | -118.38% |
| 2018 FY | - USD | -185.59% |
| 2018 Q4 | -71 Thousand USD | 99.71% |
| 2018 Q3 | -24.86 Million USD | -27.81% |
| 2018 Q2 | -19.45 Million USD | 15.96% |
| 2017 Q4 | 125.92 Million USD | 1368.9% |
| 2017 Q3 | 8.57 Million USD | 134.42% |
| 2017 Q2 | -24.9 Million USD | 7.49% |
| 2017 Q1 | -26.92 Million USD | -19.26% |
| 2017 FY | - USD | 197.35% |
| 2016 Q3 | -22.08 Million USD | -4.69% |
| 2016 Q4 | -22.57 Million USD | -2.2% |
| 2016 FY | - USD | -203.11% |
| 2016 Q2 | -21.1 Million USD | -34.57% |
| 2016 Q1 | -15.68 Million USD | -386.92% |
| 2015 Q4 | 5.46 Million USD | 123.93% |
| 2015 Q3 | -22.83 Million USD | -593.62% |
| 2015 Q2 | 4.62 Million USD | 134.29% |
| 2015 Q1 | -13.49 Million USD | -250.3% |
| 2015 FY | - USD | 56.45% |
| 2014 Q2 | -14.49 Million USD | 41.6% |
| 2014 FY | - USD | 21.63% |
| 2014 Q1 | -24.82 Million USD | -16.41% |
| 2014 Q4 | -3.85 Million USD | 79.25% |
| 2014 Q3 | -18.56 Million USD | -28.04% |
| 2013 Q3 | -18.19 Million USD | 16.64% |
| 2013 FY | - USD | -49.99% |
| 2013 Q1 | -18.2 Million USD | -312.99% |
| 2013 Q4 | -21.32 Million USD | -17.21% |
| 2013 Q2 | -21.82 Million USD | -19.9% |
| 2012 Q4 | -4.4 Million USD | 78.0% |
| 2012 Q1 | -14.9 Million USD | 18.05% |
| 2012 Q3 | -20.02 Million USD | -42.58% |
| 2012 Q2 | -14.04 Million USD | 5.73% |
| 2012 FY | - USD | -170.23% |
| 2011 FY | - USD | 63.06% |
| 2011 Q1 | -9.33 Million USD | 46.79% |
| 2011 Q2 | 3.38 Million USD | 136.24% |
| 2011 Q3 | 5.15 Million USD | 52.33% |
| 2011 Q4 | -18.18 Million USD | -452.89% |
| 2010 Q4 | -17.54 Million USD | -45.33% |
| 2010 FY | - USD | 5.78% |
| 2010 Q3 | -12.06 Million USD | -2.6% |
| 2010 Q2 | -11.76 Million USD | -3.38% |
| 2010 Q1 | -11.37 Million USD | 7.35% |
| 2009 Q1 | -14.43 Million USD | 13.78% |
| 2009 FY | - USD | -15.44% |
| 2009 Q2 | -16.73 Million USD | -15.95% |
| 2009 Q4 | -12.28 Million USD | 9.51% |
| 2009 Q3 | -13.57 Million USD | 18.89% |
| 2008 Q3 | -10.91 Million USD | 1.86% |
| 2008 FY | - USD | -79.11% |
| 2008 Q4 | -16.73 Million USD | -53.27% |
| 2008 Q2 | -11.12 Million USD | -4.91% |
| 2008 Q1 | -10.6 Million USD | -9.18% |
| 2007 Q3 | -8.15 Million USD | -42.86% |
| 2007 Q4 | -9.71 Million USD | -19.09% |
| 2007 Q1 | -5.34 Million USD | -16.15% |
| 2007 FY | - USD | -79.76% |
| 2007 Q2 | -5.7 Million USD | -6.92% |
| 2006 Q1 | -3.8 Million USD | -5.83% |
| 2006 FY | - USD | -12.45% |
| 2006 Q3 | -3.93 Million USD | -11.23% |
| 2006 Q4 | -4.59 Million USD | -16.75% |
| 2006 Q2 | -3.54 Million USD | 6.9% |
| 2005 Q2 | -2.96 Million USD | 10.21% |
| 2005 Q4 | -3.59 Million USD | 5.12% |
| 2005 FY | - USD | -52.23% |
| 2005 Q3 | -3.78 Million USD | -27.86% |
| 2005 Q1 | -3.29 Million USD | -30.0% |
| 2004 Q4 | -2.53 Million USD | 21.7% |
| 2004 Q1 | -1.1 Million USD | -1927.09% |
| 2004 Q2 | -2.07 Million USD | -86.95% |
| 2004 FY | - USD | -11229.95% |
| 2004 Q3 | -3.24 Million USD | -56.28% |
| 2003 FY | - USD | -452.66% |
| 2003 Q1 | -9074.00 USD | -315.07% |
| 2003 Q2 | -355.24 Thousand USD | 46.56% |
| 2003 Q4 | -54.71 Thousand USD | -478.29% |
| 2003 Q3 | -9462.00 USD | -95.13% |
| 2002 Q3 | -12.61 Thousand USD | 30.99% |
| 2002 Q1 | 12.35 Thousand USD | 0.0% |
| 2002 Q4 | 4219.00 USD | 133.46% |
| 2002 FY | - USD | 64.01% |
| 2002 Q2 | -18.27 Thousand USD | -247.92% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 335.196% |
| Alkermes plc | 495.04 Million USD | 8.707% |
| Agenus Inc. | -145.92 Million USD | 409.714% |
| Aptorum Group Limited | -9.59 Million USD | 4808.273% |
| Ardelyx, Inc. | -55.35 Million USD | 916.467% |
| Dyadic International, Inc. | -8.22 Million USD | 5591.632% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 155408.247% |
| Lantern Pharma Inc. | -15.78 Million USD | 2962.836% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 2369.677% |
| Novavax, Inc. | -487.39 Million USD | 192.728% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 736.33% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 675.78% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 2614.526% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 4633.979% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 887.694% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 218.943% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1974.373% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -85334.216% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 387.507% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 704.087% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 2341.912% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 2004.137% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 2060.044% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 470.136% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 275.009% |
| AlloVir, Inc. | -190.14 Million USD | 337.684% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 357.268% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 1644.695% |
| Bicycle Therapeutics plc | -183.4 Million USD | 346.427% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 373.21% |
| ChromaDex Corporation | -3.89 Million USD | 11706.24% |
| Chimerix, Inc. | -92.97 Million USD | 586.1% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 1117.058% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 501.609% |
| CRISPR Therapeutics AG | -202.7 Million USD | 322.962% |
| Precision BioSciences, Inc. | -32.04 Million USD | 1510.483% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 362.411% |
| Fortress Biotech, Inc. | -133.64 Million USD | 438.175% |
| Fortress Biotech, Inc. | -133.64 Million USD | 438.175% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 684.341% |
| ImmuCell Corporation | -2.5 Million USD | 18148.447% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 446.529% |
| Immix Biopharma, Inc. | -16.13 Million USD | 2900.923% |
| Incyte Corporation | 919.42 Million USD | 50.845% |
| Innoviva, Inc. | 248.96 Million USD | -81.534% |
| IO Biotech, Inc. | -91.22 Million USD | 595.404% |
| Jaguar Health, Inc. | -33.13 Million USD | 1464.121% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 396.988% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -344.274% |
| ContextLogic Inc. | -324 Million USD | 239.49% |
| MiMedx Group, Inc. | 40.51 Million USD | -1015.45% |
| MEI Pharma, Inc. | 26.38 Million USD | -1613.218% |
| NextCure, Inc. | -59.03 Million USD | 865.506% |
| Onconetix, Inc. | -36.7 Million USD | 1331.238% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -20121.342% |
| Opthea Limited | -200.01 Million USD | 325.952% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 16524.999% |
| Vaxcyte, Inc. | -464.88 Million USD | 197.217% |
| PDS Biotechnology Corporation | -40.08 Million USD | 1227.472% |
| Precigen, Inc. | -89.22 Million USD | 606.519% |
| Pharming Group N.V. | 9.87 Million USD | -4475.752% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 384.156% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 2085.533% |
| PureTech Health plc | -11.62 Million USD | 3987.047% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 2761.486% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 293.556% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1974.373% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 616.942% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 1660.429% |
| Acelyrin, Inc. | -381.52 Million USD | 218.458% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 3507673.6% |
| Summit Therapeutics Inc. | 1 Million USD | -45049.55% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 1453.702% |
| Senti Biosciences, Inc. | -61.33 Million USD | 836.838% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 502.432% |
| Elevation Oncology, Inc. | -41.46 Million USD | 1189.896% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 1562.422% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 7488.925% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 140893.458% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 1492.62% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 5482.885% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 868.748% |
| Seer, Inc. | -97.88 Million USD | 561.712% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 826.638% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 791.42% |
| ESSA Pharma Inc. | -26.45 Million USD | 1808.341% |
| GlycoMimetics, Inc. | -39.12 Million USD | 1255.225% |
| GT Biopharma, Inc. | 5.97 Million USD | -7458.906% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 318.656% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 6680.475% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -420.604% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 896.326% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 982.382% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 4671.168% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 183.705% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 6665.18% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 1064.421% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 291.0% |
| Aptose Biosciences Inc. | -52.26 Million USD | 964.672% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 519.466% |
| Soligenix, Inc. | -7.85 Million USD | 5855.197% |
| Century Therapeutics, Inc. | -121.2 Million USD | 472.869% |
| Kura Oncology, Inc. | -164.95 Million USD | 373.982% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 664.243% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 4580.934% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 47288.952% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 10588.443% |
| Autolus Therapeutics plc | -156.77 Million USD | 388.287% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 633.857% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 754.986% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 2367.217% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 338.78% |
| GRI Bio, Inc. | -10.89 Million USD | 4247.064% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 10108.315% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 468.918% |
| IGM Biosciences, Inc. | -253.35 Million USD | 278.383% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 535.435% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 1285.179% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 3047.947% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 2970.737% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 895.051% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 521.974% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 269.907% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 333.036% |
| Verastem, Inc. | -83.16 Million USD | 643.428% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 993.67% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 385.63% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 496.135% |
| Histogen Inc. | -10.5 Million USD | 4403.028% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 3264.96% |
| Surrozen, Inc. | -41.13 Million USD | 1198.799% |
| Organovo Holdings, Inc. | -14.8 Million USD | 3152.458% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -14092416.37% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 869.754% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 981.091% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 2198.273% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 5520.325% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 372.149% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 1017.501% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 1970.177% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 3101.965% |
| Apollomics, Inc. | -171.74 Million USD | 363.147% |
| Amarin Corporation plc | -50.9 Million USD | 987.885% |
| Mesoblast Limited | -61.33 Million USD | 836.898% |
| Turnstone Biologics Corp. | -56.23 Million USD | 903.69% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 415.603% |
| Synaptogenix, Inc. | -8.3 Million USD | 5540.224% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 3046.392% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 816.841% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 9532.332% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -105239.375% |
| Exelixis, Inc. | 196.6 Million USD | -129.879% |
| Better Therapeutics, Inc. | -38.26 Million USD | 1281.19% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 419.603% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 191.264% |
| NLS Pharmaceutics AG | -11.79 Million USD | 3931.47% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -182714.624% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 1631.712% |
| Gritstone bio, Inc. | -126.86 Million USD | 456.248% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 795.464% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 11398.828% |
| Avid Bioservices, Inc. | -11.48 Million USD | 4036.478% |
| Insmed Incorporated | -654.73 Million USD | 169.027% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 20189.042% |
| MediWound Ltd. | -4.89 Million USD | 9336.603% |
| OmniAb, Inc. | -49.73 Million USD | 1008.783% |
| Alector, Inc. | -142.89 Million USD | 416.286% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 629.001% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 966.662% |
| Zai Lab Limited | -366.57 Million USD | 223.29% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 255.502% |
| Aura Biosciences, Inc. | -83.69 Million USD | 639.986% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 300.643% |
| Immunic, Inc. | -99.11 Million USD | 555.996% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 443.242% |
| Veracyte, Inc. | -49.4 Million USD | 1014.706% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 6497.953% |
| FibroGen, Inc. | -261.4 Million USD | 272.891% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 4156.611% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 6555.161% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 2514.651% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 68.819% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 1877.779% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -1032.983% |
| TG Therapeutics, Inc. | 26.1 Million USD | -1631.598% |
| Galecto, Inc. | -37.51 Million USD | 1304.582% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 1281.098% |
| Fortrea Holdings Inc. | 167.3 Million USD | -170.142% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 436.571% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 1696.365% |
| XBiotech Inc. | -35.76 Million USD | 1363.622% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 795.464% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 792.639% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 532.671% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 1860.467% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 1205.897% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 187.51% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 906.746% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 806413.893% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 488.488% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 2138.593% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 292.266% |
| NexImmune, Inc. | -28.16 Million USD | 1704.498% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 8279.225% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 3932.569% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 90.289% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 1879.879% |
| Scopus BioPharma Inc. | -11.71 Million USD | 3958.459% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 459.127% |
| Ainos, Inc. | -8.77 Million USD | 5251.51% |
| Pluri Inc. | -20.22 Million USD | 2334.596% |
| Prothena Corporation plc | -190.1 Million USD | 337.732% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 452.538% |
| Celularity Inc. | -183.94 Million USD | 345.695% |
| Rallybio Corporation | -72.37 Million USD | 724.469% |
| Cue Biopharma, Inc. | -46.05 Million USD | 1081.384% |
| MeiraGTx Holdings plc | -57.05 Million USD | 892.167% |
| Omeros Corporation | -163.61 Million USD | 376.234% |
| Humacyte, Inc. | -96.45 Million USD | 568.543% |
| Immunocore Holdings plc | -59.64 Million USD | 857.677% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 2432.991% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 1954.903% |
| Blueprint Medicines Corporation | -474.61 Million USD | 195.225% |
| CalciMedica, Inc. | -34.18 Million USD | 1421.908% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 717.127% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 460.126% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 368.296% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 279.067% |
| Pulmatrix, Inc. | -12.64 Million USD | 3673.834% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 1470.949% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 610.865% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 189.262% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 546.522% |
| Cytokinetics, Incorporated | -456.68 Million USD | 198.963% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 1454.229% |
| Nutriband Inc. | -5.12 Million USD | 8924.027% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 1144.433% |
| Vor Biopharma Inc. | -114.37 Million USD | 495.159% |
| Roivant Sciences Ltd. | -996.51 Million USD | 145.353% |
| Evogene Ltd. | -23.2 Million USD | 2047.712% |
| ProKidney Corp. | -147.66 Million USD | 406.054% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 800.313% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 295202.808% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 179.924% |
| CorMedix Inc. | -48.88 Million USD | 1024.472% |
| BioLineRx Ltd. | -57.06 Million USD | 892.042% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 504.398% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 223836.139% |
| Atai Life Sciences N.V. | -36.31 Million USD | 1344.656% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 668.365% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 655.811% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 264.044% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 1570.224% |
| MediciNova, Inc. | -9.87 Million USD | 4674.376% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 458.856% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 29635.14% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1794.668% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 300.873% |
| Biomea Fusion, Inc. | -124.62 Million USD | 462.66% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 236.813% |
| Mereo BioPharma Group plc | -26.05 Million USD | 1834.522% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 337.443% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 296.548% |
| Absci Corporation | -95.45 Million USD | 573.456% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1605.236% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 521.915% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 293.573% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 2077.454% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 317.454% |
| Allakos Inc. | -189.91 Million USD | 337.973% |
| Imunon, Inc. | -19.87 Million USD | 2373.572% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 516.572% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -317.218% |
| BioAtla, Inc. | -122.24 Million USD | 469.718% |
| NLS Pharmaceutics AG | -11.79 Million USD | 3931.47% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 2967.502% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 250.502% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 1190.422% |
| XOMA Corporation | -39.36 Million USD | 1248.181% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 555.344% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 484.145% |
| aTyr Pharma, Inc. | -52.17 Million USD | 966.164% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 639.22% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 404.073% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 292.675% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 3410.24% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 5719.624% |
| Akari Therapeutics, Plc | -16.8 Million USD | 2789.84% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -239397.949% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 7174.245% |
| UroGen Pharma Ltd. | -63.83 Million USD | 808.037% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 765.46% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 6322.584% |
| Orgenesis Inc. | -60.71 Million USD | 844.338% |
| Entera Bio Ltd. | -8.8 Million USD | 5233.428% |
| GH Research PLC | -41.15 Million USD | 1198.212% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 1871.022% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 649.593% |
| Xencor, Inc. | -125.87 Million USD | 459.047% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 31781.23% |
| Replimune Group, Inc. | -230.19 Million USD | 296.33% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 2342.066% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 4230.387% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 7174.245% |
| Portage Biotech Inc. | -18.19 Million USD | 2583.362% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 29635.14% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 532.138% |
| OncoCyte Corporation | -23.12 Million USD | 2054.534% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 4099.403% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 4044.779% |
| Purple Biotech Ltd. | -22.22 Million USD | 2133.507% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 7150.655% |
| scPharmaceuticals Inc. | -46.06 Million USD | 1081.192% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 2637.648% |
| HilleVax, Inc. | -132.46 Million USD | 441.18% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 4350.419% |
| Tharimmune, Inc. | -9.3 Million USD | 4958.293% |
| Genprex, Inc. | -31.06 Million USD | 1555.051% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 341.005% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 1541.433% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 59255.366% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -299393.055% |
| OKYO Pharma Limited | -15.74 Thousand USD | 2870357.407% |
| Savara Inc. | -59.13 Million USD | 864.289% |
| Curis, Inc. | -45.13 Million USD | 1101.234% |
| Daré Bioscience, Inc. | -30.7 Million USD | 1572.067% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 3075.068% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 6407.704% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 1790.533% |
| BeiGene, Ltd. | -1.12 Billion USD | 140.187% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 2872.477% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 204.962% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 600.273% |
| Erasca, Inc. | -121.31 Million USD | 472.555% |
| bluebird bio, Inc. | -167.16 Million USD | 370.366% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 10146.044% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -45.656% |
| DBV Technologies S.A. | -85.98 Million USD | 625.63% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 10146.044% |
| Moderna, Inc. | -3.28 Billion USD | 113.766% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 1160.684% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 8101.894% |
| Molecular Templates, Inc. | 1.43 Million USD | -31504.685% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 855.108% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 238.53% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 429.674% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 1054.159% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 425.062% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 319.541% |
| MacroGenics, Inc. | 2.01 Million USD | -22306.891% |
| RenovoRx, Inc. | -11.39 Million USD | 4067.928% |
| Adicet Bio, Inc. | -136.53 Million USD | 431.012% |
| Prime Medicine, Inc. | -193.75 Million USD | 333.252% |
| Aditxt, Inc. | -25.45 Million USD | 1875.268% |
| Adagene Inc. | -14.95 Million USD | 3122.898% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 6282.503% |
| Quantum-Si incorporated | -91.8 Million USD | 592.296% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 36.561% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -257.397% |
| SciSparc Ltd. | -5.28 Million USD | 8656.361% |
| Vericel Corporation | 2.86 Million USD | -15680.272% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 474794.353% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 2183.528% |
| Generation Bio Co. | -133.3 Million USD | 439.045% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 644.318% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 625.379% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 298.716% |
| Invivyd, Inc. | -196.61 Million USD | 329.864% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 220.792% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 4972.85% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -1564.385% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 4494.234% |
| 2seventy bio, Inc. | -206.41 Million USD | 318.947% |
| ADMA Biologics, Inc. | 5.12 Million USD | -8727.09% |
| Clene Inc. | -43.24 Million USD | 1145.182% |
| Capricor Therapeutics, Inc. | -23 Million USD | 2064.22% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 1032.292% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1794.668% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 250.867% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 1330.479% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -1817.223% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -9104.145% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 1491.377% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 385.313% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 166.045% |
| Evaxion Biotech A/S | -21.4 Million USD | 2211.606% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 780.489% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 307.63% |
| Trevena, Inc. | -35.28 Million USD | 1380.738% |
| Surrozen, Inc. | -41.13 Million USD | 1198.799% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 667.83% |
| Cingulate Inc. | -22.95 Million USD | 2069.094% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 6157.459% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 1312.207% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 5593.881% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 541.933% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 766.323% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 874.253% |
| Clearmind Medicine Inc. | -8.71 Million USD | 5288.434% |
| Kronos Bio, Inc. | -121.83 Million USD | 470.965% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 707.93% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 18611.69% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 548.24% |
| Statera Biopharma, Inc. | 38.93 Million USD | -1060.774% |
| ImmunityBio, Inc. | -436.18 Million USD | 203.614% |
| Korro Bio, Inc. | -80.9 Million USD | 658.621% |
| Kineta, Inc. | -15.71 Million USD | 2976.079% |
| BioVie Inc. | -31.95 Million USD | 1514.535% |
| Codexis, Inc. | -49.28 Million USD | 1017.044% |
| Celularity Inc. | -183.94 Million USD | 345.695% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 304.03% |
| Celcuity Inc. | -58.3 Million USD | 875.077% |
| Virax Biolabs Group Limited | -6.6 Million USD | 6938.208% |
| Cibus, Inc. | -314.58 Million USD | 243.665% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 1439.777% |
| IN8bio, Inc. | -28.5 Million USD | 1685.556% |
| Kodiak Sciences Inc. | -259.02 Million USD | 274.481% |
| Annexon, Inc. | -141.57 Million USD | 419.228% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 501.377% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 804.011% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 1716.695% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 296.49% |
| Eyenovia, Inc. | -24.1 Million USD | 1974.829% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -909.171% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 139589.815% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 712.361% |
| Arcellx, Inc. | -64.14 Million USD | 804.571% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 1104.014% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 466.02% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 1563.464% |
| Moolec Science SA | -52.07 Million USD | 967.868% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 975.764% |
| Geron Corporation | -174.78 Million USD | 358.578% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 1218.21% |
| Royalty Pharma plc | 1.88 Billion USD | 76.053% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 477.904% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 4947.004% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 2279.029% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 372.126% |
| Humacyte, Inc. | -96.45 Million USD | 568.543% |
| Structure Therapeutics Inc. | -102.45 Million USD | 541.1% |
| 89bio, Inc. | -134.46 Million USD | 436.113% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 672.991% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -11053.677% |
| Genelux Corporation | -24.16 Million USD | 1970.255% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 1437.121% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 376.481% |
| Notable Labs, Ltd. | -14.4 Million USD | 3238.521% |
| Liquidia Corporation | -70.05 Million USD | 745.169% |
| Mustang Bio, Inc. | -48.06 Million USD | 1040.322% |
| Immunovant, Inc. | -269.97 Million USD | 267.401% |
| Quantum-Si incorporated | -91.8 Million USD | 592.296% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 736.671% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 2440.724% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 543.033% |
| Acasti Pharma Inc. | -11.3 Million USD | 4099.177% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 2130.927% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 3047.947% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 314.688% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 10683.389% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 2946.014% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 1670.569% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 1320.489% |
| PepGen Inc. | -83.58 Million USD | 640.723% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 1631.816% |
| United Therapeutics Corporation | 1.38 Billion USD | 67.411% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 2073.826% |
| Solid Biosciences Inc. | -93.43 Million USD | 583.707% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 9571.333% |
| Immuneering Corporation | -58.06 Million USD | 878.403% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -14092416.37% |
| Silo Pharma, Inc. | -3.62 Million USD | 12563.33% |
| Belite Bio, Inc | -31.52 Million USD | 1533.433% |
| XOMA Corporation | -39.36 Million USD | 1248.181% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 770.077% |
| Bionomics Limited | -9.83 Million USD | 4694.36% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 638.128% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 1405.979% |
| uniQure N.V. | -253.1 Million USD | 278.565% |
| Cassava Sciences, Inc. | -95.68 Million USD | 572.318% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 6282.503% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 448.983% |
| Forte Biosciences, Inc. | -32.47 Million USD | 1491.591% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 5713.919% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 1701.57% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 139589.815% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 4156.611% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 2942.255% |
| Altimmune, Inc. | -87.93 Million USD | 613.956% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 590.825% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 1405.979% |
| Compugen Ltd. | -12.51 Million USD | 3710.954% |
| Peak Bio, Inc. | -1356.23 USD | 33323872.516% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 1029.97% |
| Benitec Biopharma Inc. | -22.49 Million USD | 2109.546% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 286.521% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 1683.39% |
| Zura Bio Limited | -60.56 Million USD | 846.243% |
| PolyPid Ltd. | -20.26 Million USD | 2330.405% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 2994.684% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 1683.39% |
| Instil Bio, Inc. | -146.12 Million USD | 409.294% |
| argenx SE | -216.02 Million USD | 309.212% |
| Immunome, Inc. | -28.27 Million USD | 1698.624% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 1032.369% |
| Verona Pharma plc | -52.46 Million USD | 961.383% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 576.878% |
| Shattuck Labs, Inc. | -87.61 Million USD | 615.833% |
| CervoMed Inc. | -2.17 Million USD | 20909.08% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 469.709% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 3660.6% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 1038.155% |
| Moolec Science SA | -52.07 Million USD | 967.868% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 2736.799% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 446.609% |
| AnaptysBio, Inc. | -143.16 Million USD | 415.685% |
| Design Therapeutics, Inc. | -66.32 Million USD | 781.413% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 658.049% |
| NeurAxis, Inc. | -6.66 Million USD | 6881.414% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 1297.211% |
| Lumos Pharma, Inc. | -36.57 Million USD | 1335.841% |
| Achilles Therapeutics plc | -70.44 Million USD | 741.587% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 576.878% |
| 180 Life Sciences Corp. | -22.13 Million USD | 2141.865% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -7653.094% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 18611.69% |
| Nutriband Inc. | -5.12 Million USD | 8924.027% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 511.804% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 915.318% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 994.059% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 792.353% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 935.238% |
| Palisade Bio, Inc. | -12.28 Million USD | 3780.05% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 1096.004% |
| Beam Therapeutics Inc. | -156.47 Million USD | 388.834% |
| Neurogene Inc. | -52.28 Million USD | 964.375% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 431.121% |
| AEON Biopharma, Inc. | -48.36 Million USD | 1034.528% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 585.87% |
| Sesen Bio, Inc. | -50.84 Million USD | 988.959% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 651.612% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 3759.483% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 205.735% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 529.62% |
| Athira Pharma, Inc. | -116.7 Million USD | 487.263% |
| Vaccinex, Inc. | -19.74 Million USD | 2388.571% |
| HCW Biologics Inc. | -23.57 Million USD | 2016.975% |
| XOMA Corporation | -39.36 Million USD | 1248.181% |
| Nektar Therapeutics | -243.1 Million USD | 285.905% |
| Arvinas, Inc. | -394.8 Million USD | 214.475% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -239397.949% |
| Merus N.V. | -149.2 Million USD | 402.899% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 583.417% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 1545.768% |
| Rezolute, Inc. | -68.42 Million USD | 760.519% |
| Clene Inc. | -43.24 Million USD | 1145.182% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 3030.498% |
| BeyondSpring Inc. | -21.54 Million USD | 2198.175% |
| Synlogic, Inc. | -55.16 Million USD | 919.323% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 3840.354% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 4346.824% |
| Peak Bio, Inc. | -1356.23 USD | 33323872.516% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 1492.105% |
| Krystal Biotech, Inc. | 17.9 Million USD | -2424.279% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 481.638% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 232.401% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 9911.216% |
| MannKind Corporation | 15.12 Million USD | -2887.289% |
| Ikena Oncology, Inc. | -74.39 Million USD | 707.48% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 3688.875% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -2123.383% |
| Gossamer Bio, Inc. | -172.15 Million USD | 362.528% |
| CohBar, Inc. | -12.06 Million USD | 3845.699% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 1871.716% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1605.236% |
| Legend Biotech Corporation | -477.87 Million USD | 194.575% |
| Mural Oncology plc | -192.72 Million USD | 334.51% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 496.257% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 2899.253% |
| Disc Medicine, Inc. | -91.02 Million USD | 596.509% |
| Champions Oncology, Inc. | -5.05 Million USD | 9042.362% |
| REGENXBIO Inc. | -239.46 Million USD | 288.733% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 4316.637% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 910.58% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 1265.765% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 500.641% |
| Vaxart, Inc. | -74.72 Million USD | 704.83% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 1383.638% |
| Cellectis S.A. | -98.09 Million USD | 560.724% |
| Longeveron Inc. | -20.06 Million USD | 2352.976% |
| Repare Therapeutics Inc. | -114.27 Million USD | 495.498% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 202.903% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 704.11% |
| Revolution Medicines, Inc. | -430.58 Million USD | 204.962% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 7286.309% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 1567.885% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 705.908% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -9117.765% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 4221.724% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 90.186% |
| Denali Therapeutics Inc. | -179.97 Million USD | 351.119% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 474794.353% |
| Veru Inc. | -89.97 Million USD | 602.3% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 1781.476% |
| Cingulate Inc. | -22.95 Million USD | 2069.094% |
| Passage Bio, Inc. | -98.34 Million USD | 559.571% |
| Context Therapeutics Inc. | -25.06 Million USD | 1903.419% |
| Exicure, Inc. | -15.53 Million USD | 3008.469% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 319.324% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 1322.271% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 7679.702% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 368.275% |
| Nuvalent, Inc. | -149.49 Million USD | 402.322% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 5657.353% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 626.168% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 1597.604% |
| OmniAb, Inc. | -49.73 Million USD | 1008.783% |
| Anew Medical, Inc. | -1.3 Million USD | 34842.705% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 3755.346% |
| Lipocine Inc. | -16.32 Million USD | 2868.831% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 777.887% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 708.249% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 1285.179% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 1258.423% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 2137.357% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 182.915% |
| Ocugen, Inc. | -64.82 Million USD | 797.159% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 588.222% |
| Q32 Bio Inc. | -86.5 Million USD | 622.47% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 2769.977% |
| Alumis Inc. Common Stock | -156.89 Million USD | 388.066% |
| Equillium, Inc. | -12.13 Million USD | 3823.406% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 872.929% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 5818.424% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 2496.202% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 1067.932% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 524.982% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 2626.737% |
| Dominari Holdings Inc. | -22.44 Million USD | 2114.024% |
| Edesa Biotech, Inc. | -8.19 Million USD | 5618.183% |
| vTv Therapeutics Inc. | -25.41 Million USD | 1878.479% |
| Bio-Techne Corporation | 326.66 Million USD | -38.353% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 217.43% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -108.859% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 444.714% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 1307.414% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 399.103% |
| Nkarta, Inc. | -120.48 Million USD | 475.119% |
| BioCardia, Inc. | -11.56 Million USD | 4009.576% |
| Iterum Therapeutics plc | -34.58 Million USD | 1406.961% |